The liver cancer drug market size has grown rapidly in recent years. It will grow from $2.62 billion in 2025 to $2.93 billion in 2026 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to increasing incidence of hepatocellular carcinoma, rising prevalence of chronic liver diseases, expansion of oncology clinical trials, improved cancer diagnosis rates, availability of advanced chemotherapy regimens.
The liver cancer drug market size is expected to see rapid growth in the next few years. It will grow to $4.62 billion in 2030 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to increasing approvals of novel immunotherapies, rising investments in oncology R&D, expansion of personalized cancer treatment approaches, growing demand for combination therapies, increasing focus on early-stage liver cancer treatment. Major trends in the forecast period include increasing adoption of targeted liver cancer therapies, rising use of immunotherapy combinations, expansion of precision oncology drug development, growing focus on biomarker-based treatment selection, enhanced integration of companion diagnostics.
The growing investment in research and development is expected to drive the expansion of the liver cancer drug market. Research and development involve a systematic process of investigating, designing, and assessing new products, technologies, or techniques to enhance knowledge and deliver innovative solutions to the market. The increase in research and development is driven by a rising demand for innovation and technological progress across industries, prompting companies to develop new products and improve existing ones to remain competitive. In the context of liver cancer drugs, research and development support the discovery of targeted therapies that enhance treatment efficacy while minimizing harm to healthy liver tissue. For example, in September 2024, Cancer Research UK, a UK-based cancer research organization, reported an investment of $533 million (£399 million) in cancer research during the 2023/24 financial year, with $124 million (£93 million) allocated to research relevant to all cancer types and $112 million (£84 million) directed to fundamental biological studies. Therefore, the increase in research and development activities is contributing to the growth of the liver cancer drug market.
Key players in the liver cancer drug market are prioritizing the development of innovative treatments, including advanced therapies, to improve treatment accuracy and patient outcomes. Advanced liver cancer therapies encompass novel approaches such as immunotherapy, targeted therapy, gene therapy, CAR-T cell therapy, and minimally invasive techniques such as TACE and ablation, which aim to increase the effectiveness and precision of liver cancer treatment. For instance, in November 2023, Terumo India, an India-based medical device manufacturer, launched advanced Balloon-TACE therapy for liver cancer in India, featuring two innovative devices, Occlusafe and LifePearl. These devices are designed to enhance the accuracy and efficiency of transcatheter arterial chemoembolization (TACE) by delivering chemotherapy directly to liver tumors while limiting damage to healthy tissue and maintaining liver function, specifically targeting hepatocellular carcinoma, the most prevalent form of liver cancer in India.
In September 2023, Coherus BioSciences Inc., a US-based biopharmaceutical firm, completed the acquisition of Surface Oncology Inc. for an undisclosed amount. Through this acquisition, Coherus expanded its immuno-oncology pipeline to include several antibody-based immunotherapy candidates. These treatments are intended to enhance both innate and adaptive immune system responses, ultimately improving therapeutic outcomes for cancer patients. Surface Oncology Inc. is a US-based company specializing in the development of liver cancer drugs.
Major companies operating in the liver cancer drug market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Novartis AG, Takeda Pharmaceutical Company Limited, Hetero Drugs Limited, Sun pharma, Eisai Company Limited, Genentech Incorporated, Ipsen Société Anonyme, Cipla Limited, Dr. Reddy’s Laboratories Limited, BeiGene Ltd., Exelixis Incorporated, Natco Pharma Limited, MacroGenics Inc.
North America was the largest region in the liver cancer drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liver cancer drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the liver cancer drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the liver cancer drug market by increasing costs of imported active pharmaceutical ingredients, biologics, specialized reagents, and advanced manufacturing equipment used in targeted therapies and immunotherapies. Pharmaceutical manufacturers in North America and Europe are most affected due to dependence on global API supply chains, while Asia-Pacific faces cost pressures on export-oriented drug production. These tariffs are contributing to higher production costs and longer development timelines. However, they are also encouraging localized API manufacturing, regional clinical production facilities, and strategic supply chain diversification to strengthen long-term drug availability.
The liver cancer drug market research report is one of a series of new reports that provides liver cancer drug market statistics, including liver cancer drug industry global market size, regional shares, competitors with a liver cancer drug market share, detailed liver cancer drug market segments, market trends and opportunities, and any further data you may need to thrive in the liver cancer drug industry. This liver cancer drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Liver cancer drugs are a category of pharmaceutical substances formulated to address the growth of malignant cells in a critical organ responsible for detoxification, metabolism, and nutrient storage. These medications function by interfering with the biological processes that support the proliferation, division, and immune evasion of abnormal cells.
The primary categories of liver cancer drugs include treatments for hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, and others. Hepatocellular carcinoma (HCC) is the most prevalent form of primary liver cancer, indicating it originates within the liver rather than metastasizing from another organ. Treatment options encompass targeted therapy, immunotherapy, chemotherapy, and others, which may be administered orally or via injection. These drugs are distributed through multiple channels, such as hospital pharmacies, retail pharmacies, and online platforms.
The liver cancer drug market consists of revenues earned by entities by providing services such as clinical trial management, pharmacovigilance services, and personalized treatment planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver cancer drug market also includes sales of monoclonal antibodies, hormonal therapy drugs, gene therapy products, and liver-specific drug delivery systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The liver cancer drug market size is expected to see rapid growth in the next few years. It will grow to $4.62 billion in 2030 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to increasing approvals of novel immunotherapies, rising investments in oncology R&D, expansion of personalized cancer treatment approaches, growing demand for combination therapies, increasing focus on early-stage liver cancer treatment. Major trends in the forecast period include increasing adoption of targeted liver cancer therapies, rising use of immunotherapy combinations, expansion of precision oncology drug development, growing focus on biomarker-based treatment selection, enhanced integration of companion diagnostics.
The growing investment in research and development is expected to drive the expansion of the liver cancer drug market. Research and development involve a systematic process of investigating, designing, and assessing new products, technologies, or techniques to enhance knowledge and deliver innovative solutions to the market. The increase in research and development is driven by a rising demand for innovation and technological progress across industries, prompting companies to develop new products and improve existing ones to remain competitive. In the context of liver cancer drugs, research and development support the discovery of targeted therapies that enhance treatment efficacy while minimizing harm to healthy liver tissue. For example, in September 2024, Cancer Research UK, a UK-based cancer research organization, reported an investment of $533 million (£399 million) in cancer research during the 2023/24 financial year, with $124 million (£93 million) allocated to research relevant to all cancer types and $112 million (£84 million) directed to fundamental biological studies. Therefore, the increase in research and development activities is contributing to the growth of the liver cancer drug market.
Key players in the liver cancer drug market are prioritizing the development of innovative treatments, including advanced therapies, to improve treatment accuracy and patient outcomes. Advanced liver cancer therapies encompass novel approaches such as immunotherapy, targeted therapy, gene therapy, CAR-T cell therapy, and minimally invasive techniques such as TACE and ablation, which aim to increase the effectiveness and precision of liver cancer treatment. For instance, in November 2023, Terumo India, an India-based medical device manufacturer, launched advanced Balloon-TACE therapy for liver cancer in India, featuring two innovative devices, Occlusafe and LifePearl. These devices are designed to enhance the accuracy and efficiency of transcatheter arterial chemoembolization (TACE) by delivering chemotherapy directly to liver tumors while limiting damage to healthy tissue and maintaining liver function, specifically targeting hepatocellular carcinoma, the most prevalent form of liver cancer in India.
In September 2023, Coherus BioSciences Inc., a US-based biopharmaceutical firm, completed the acquisition of Surface Oncology Inc. for an undisclosed amount. Through this acquisition, Coherus expanded its immuno-oncology pipeline to include several antibody-based immunotherapy candidates. These treatments are intended to enhance both innate and adaptive immune system responses, ultimately improving therapeutic outcomes for cancer patients. Surface Oncology Inc. is a US-based company specializing in the development of liver cancer drugs.
Major companies operating in the liver cancer drug market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Novartis AG, Takeda Pharmaceutical Company Limited, Hetero Drugs Limited, Sun pharma, Eisai Company Limited, Genentech Incorporated, Ipsen Société Anonyme, Cipla Limited, Dr. Reddy’s Laboratories Limited, BeiGene Ltd., Exelixis Incorporated, Natco Pharma Limited, MacroGenics Inc.
North America was the largest region in the liver cancer drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liver cancer drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the liver cancer drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the liver cancer drug market by increasing costs of imported active pharmaceutical ingredients, biologics, specialized reagents, and advanced manufacturing equipment used in targeted therapies and immunotherapies. Pharmaceutical manufacturers in North America and Europe are most affected due to dependence on global API supply chains, while Asia-Pacific faces cost pressures on export-oriented drug production. These tariffs are contributing to higher production costs and longer development timelines. However, they are also encouraging localized API manufacturing, regional clinical production facilities, and strategic supply chain diversification to strengthen long-term drug availability.
The liver cancer drug market research report is one of a series of new reports that provides liver cancer drug market statistics, including liver cancer drug industry global market size, regional shares, competitors with a liver cancer drug market share, detailed liver cancer drug market segments, market trends and opportunities, and any further data you may need to thrive in the liver cancer drug industry. This liver cancer drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Liver cancer drugs are a category of pharmaceutical substances formulated to address the growth of malignant cells in a critical organ responsible for detoxification, metabolism, and nutrient storage. These medications function by interfering with the biological processes that support the proliferation, division, and immune evasion of abnormal cells.
The primary categories of liver cancer drugs include treatments for hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, and others. Hepatocellular carcinoma (HCC) is the most prevalent form of primary liver cancer, indicating it originates within the liver rather than metastasizing from another organ. Treatment options encompass targeted therapy, immunotherapy, chemotherapy, and others, which may be administered orally or via injection. These drugs are distributed through multiple channels, such as hospital pharmacies, retail pharmacies, and online platforms.
The liver cancer drug market consists of revenues earned by entities by providing services such as clinical trial management, pharmacovigilance services, and personalized treatment planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver cancer drug market also includes sales of monoclonal antibodies, hormonal therapy drugs, gene therapy products, and liver-specific drug delivery systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Liver Cancer Drug Market Characteristics
3. Liver Cancer Drug Market Supply Chain Analysis
4. Global Liver Cancer Drug Market Trends and Strategies
5. Liver Cancer Drug Market Analysis of End Use Industries
7. Global Liver Cancer Drug Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Liver Cancer Drug Total Addressable Market (TAM) Analysis for the Market
9. Liver Cancer Drug Market Segmentation
10. Liver Cancer Drug Market Regional and Country Analysis
11. Asia-Pacific Liver Cancer Drug Market
12. China Liver Cancer Drug Market
13. India Liver Cancer Drug Market
14. Japan Liver Cancer Drug Market
15. Australia Liver Cancer Drug Market
16. Indonesia Liver Cancer Drug Market
17. South Korea Liver Cancer Drug Market
18. Taiwan Liver Cancer Drug Market
19. South East Asia Liver Cancer Drug Market
20. Western Europe Liver Cancer Drug Market
21. UK Liver Cancer Drug Market
22. Germany Liver Cancer Drug Market
23. France Liver Cancer Drug Market
24. Italy Liver Cancer Drug Market
25. Spain Liver Cancer Drug Market
26. Eastern Europe Liver Cancer Drug Market
27. Russia Liver Cancer Drug Market
28. North America Liver Cancer Drug Market
29. USA Liver Cancer Drug Market
30. Canada Liver Cancer Drug Market
31. South America Liver Cancer Drug Market
32. Brazil Liver Cancer Drug Market
33. Middle East Liver Cancer Drug Market
34. Africa Liver Cancer Drug Market
36. Liver Cancer Drug Market Competitive Landscape and Company Profiles
37. Liver Cancer Drug Market Other Major and Innovative Companies
40. Liver Cancer Drug Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Liver Cancer Drug Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses liver cancer drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for liver cancer drug? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The liver cancer drug market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Hepatocellular Carcinoma; Cholangio Carcinoma; Hepatoblastoma; Other Types2) By Therapy: Targeted Therapy; Immunotherapy; Chemotherapy; Other Therapies
3) By Route Of Administration: Oral; Injectable
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Hepatocellular Carcinoma: Targeted Therapy; Immunotherapy; Chemotherapy; Combination Therapy2) By Cholangio Carcinoma: Targeted Therapy; Chemotherapy; Immunotherapy
3) By Hepatoblastoma: Chemotherapy; Targeted Therapy; Immunotherapy; Surgical Adjuvants
4) By Other Types: Chemotherapy; Targeted Therapy; Experimental Or Off-label Therapies; Supportive Care Medications
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; AstraZeneca plc; Bayer AG; Bristol-Myers Squibb Company; Eli Lilly and Company; Novartis AG; Takeda Pharmaceutical Company Limited; Hetero Drugs Limited; Sun pharma; Eisai Company Limited; Genentech Incorporated; Ipsen Société Anonyme; Cipla Limited; Dr. Reddy’s Laboratories Limited; BeiGene Ltd.; Exelixis Incorporated; Natco Pharma Limited; MacroGenics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Liver Cancer Drug market report include:- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- Merck & Co. Inc.
- AstraZeneca plc
- Bayer AG
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Novartis AG
- Takeda Pharmaceutical Company Limited
- Hetero Drugs Limited
- Sun pharma
- Eisai Company Limited
- Genentech Incorporated
- Ipsen Société Anonyme
- Cipla Limited
- Dr. Reddy’s Laboratories Limited
- BeiGene Ltd.
- Exelixis Incorporated
- Natco Pharma Limited
- MacroGenics Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.93 Billion |
| Forecasted Market Value ( USD | $ 4.62 Billion |
| Compound Annual Growth Rate | 12.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
